✦ LIBER ✦

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

✍ Scribed by Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 85 KB
Volume: 12
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.20562

No coin nor oath required. For personal study only.

✦ Synopsis

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a day for 90 days, GCV) in preventing CMV disease in 109 adult liver transplant recipients who survived at least 1 month between January 2001 and April 2003 (49 GCV and 60 VGCV). The incidence of CMV disease at 1 year post-transplant was similar among patients treated with VGCV and GCV (3% and 4%, respectively). Three of the four CMV disease cases occurred in high-risk recipients with CMV serotype of donor+/recipient- (D+/R-) and all cases presented after completion of CMV prophylaxis, ranging 114-152 days post-transplant. Severe neutropenia was rare, and thrombocytopenia and anemia occurred at similar frequencies with both prophylaxis regimens. In conclusion, a 90-day regimen of low-dose oral VGCV has a similar efficacy and safety profile to high-dose oral GCV in adult liver transplant recipients. D+/R- liver transplant recipients remain at risk of developing CMV disease after completion of antiviral prophylaxis. Additional prospective studies with close monitoring for CMV viremia and drug resistance are needed to further establish the optimal dose and duration of VGCV in liver transplant recipients.

📜 SIMILAR VOLUMES

Efficacy of influenza vaccination in adu

Efficacy of influenza vaccination in adult liver transplant recipients

✍ Soesman, N.M.R.; Rimmelzwaan, G.F.; Nieuwkoop, N.J.; Beyer, W.E.P.; Tilanus, H.W 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 284 KB 👁 2 views

To assess the efficacy of influenza vaccination in immunocompromised adult liver transplant (LTx) recipients, the serum antibody responses of 61 of these patients and 35 liver cirrhosis patients with those of 45 of their healthy spouses were compared, after one and two vaccinations with a commercial

Valganciclovir as preemptive therapy for

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts

✍ Nina Singh; Cheryl Wannstedt; Lois Keyes; Debra Mayher; Lisa Tickerhoof; Mohamed 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient-negative/donor-positive (RϪ/Dϩ) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institutio

Question of using valganciclovir for cyt

Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients

✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n ϭ 49) compared with the standard dose of ganciclovir (n ϭ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au

Efficacy and safety of valganciclovir in

Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus

✍ Loreto Hierro; Ruth Díez-Dorado; Carmen Díaz; Angela De la Vega; Esteban Frauca; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 1 views

Epstein-Barr virus (EBV) infection after liver transplantation (LT) is associated with increased risk of posttransplant lymphoproliferative disorder (PTLD). Lowering immunosuppression is the current method to prevent PTLD in LT children with a high viral load. The aim of this study was to assess the

Pharmacokinetics, efficacy, and safety o

Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients

✍ Björn Nashan; Faouzi Saliba; Francois Durand; Rafael Barcéna; Jose Ignacio Herre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 455 KB 👁 1 views

The pharmacokinetics of mycophenolate mofetil (MMF) in liver transplant recipients may change because of pharmacokinetic interactions with coadministered immunosuppressants or because changes in the enterohepatic anatomy may affect biotransformation of MMF to mycophenolic acid (MPA) and enterohepati

Increased incidence of cytomegalovirus i

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis

✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos